Latest 10-K annual reports

Windtree Therapeutics reports its 2024 10-K filing, highlighting financial uncertainties alongside progress in its cardiovascular and oncology programs.

Omnitek Engineering Corp. reports a slight decrease in revenue and a reduced net loss for the fiscal year ended December 31, 2024, while acknowledging ongoing concerns about its ability to continue as a going concern.

Matinas BioPharma's 10-K filing details its capital structure, strategic shift towards partnering for MAT2203, and ongoing efforts to explore strategic alternatives.

Moveix Inc.'s Form 10-K filing reveals the company's continued efforts to identify and acquire an operating business amidst financial uncertainties and a going concern warning.

XWELL, Inc. reports a 13% increase in total revenue for 2024, driven by Naples Wax acquisition and XpresSpa's touchless locations, while addressing going concern doubts and material weaknesses in internal controls.

TruGolf Holdings provides a detailed overview of its capital stock, governance structure, and risk factors in its latest 10-K filing.

Broad Capital Acquisition Corp.'s 10-K filing reveals a net loss, termination of the Openmarkets merger, and substantial doubt about its ability to continue as a going concern.

Southport Acquisition Corporation's 10-K filing reveals substantial doubt about its ability to continue as a going concern, despite a proposed merger with Angel Studios.

Nuburu's 10-K filing reveals substantial losses, a shift in business strategy following a foreclosure, and a focus on strategic acquisitions to diversify its asset base.

MIRA Pharmaceuticals files an amendment to its annual report on Form 10-K to include a policy regarding the recovery of erroneously awarded compensation.

GameSquare Holdings' 2024 10-K filing reveals significant revenue growth due to strategic acquisitions, but also highlights material weaknesses in internal controls and a net loss.

Aimfinity Investment Corp. I amends its charter to extend the period for completing a business combination, allowing for up to nine additional one-month extensions.

Slam Corp's 10-K filing reveals substantial doubt about its ability to continue as a going concern as it navigates challenges in completing its initial business combination with Lynk Global.

Vaccinex's 10-K filing reveals a clinical-stage biotech company prioritizing Alzheimer's disease treatment while navigating financial challenges and strategic partnerships.

GiveMePower Corporation's 10-K filing details a strategic shift towards fintech, a pause in real estate acquisitions due to interest rate concerns, and ongoing efforts to empower black communities through financial tools and resources.

SMC Entertainment's 10-K filing reveals a substantial net loss of $8.43 million for 2024 and expresses substantial doubt about the company's ability to continue as a going concern.

Micromobility.com transitions to a technology-focused enterprise, providing software development and business services, while reporting financial results for the year ended December 31, 2024.

Moatable, Inc. saw its net loss decrease in FY2024, driven by growth in its SaaS businesses, Lofty and Trucker Path.

Golden Minerals reports a net loss for 2024 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Vestiage, Inc. reports a net loss of $52,675 for the year ended December 31, 2024, and expresses substantial doubt about its ability to continue as a going concern.

Dream Homes & Development Corporation reports a net income of $875,966 for 2024, shifting its focus towards build-to-lease properties and improved lots for sale to capitalize on market trends.

Selectis Health saw a revenue increase in 2024, but faces significant financial challenges raising substantial doubt about its ability to continue as a going concern.

PrimeEnergy Resources Corporation's 10-K filing reveals a significant increase in oil and gas production and proved reserves for the fiscal year ended December 31, 2024, driven by horizontal drilling activities, primarily in the Midland Basin of West Texas.

FOXO Technologies amends its termination agreement with KR8 AI to clarify the scope of the termination, focusing on financial obligations rather than the entire agreement.

TriSalus Life Sciences reports a 59% increase in revenue for 2024, driven by its TriNav Infusion System, while continuing to develop its immunotherapeutic, nelitolimod.

SUNation Energy's 10-K filing reveals delisting concerns, material weaknesses in internal controls, and a strategic shift towards Bitcoin amidst ongoing financial challenges.

Yuenglings Ice Cream Corporation, rebranding as a technology holding company, reports a net profit of $4.39 million for 2024, driven by fair market value changes and debt extinguishment gains, while strategically divesting its ice cream assets.

Oncotelic Therapeutics' 2024 annual report details ongoing efforts to develop cancer treatments, manage financial constraints, and advance strategic partnerships, particularly through its joint venture GMP Biotechnology.

Eyenovia is exploring strategic alternatives and cutting costs after a negative clinical trial result, raising concerns about its ability to continue as a going concern.

Royalty Management Holding Corporation files an amendment to its 2024 annual report to include a compensation clawback policy.